Form 4 for AUPH Aurinia Pharmaceuticals Inc.
Accepted 2021-09-14 00:00:00 ET · period of report 2021-09-10 · accession 0001628280-21-018595 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2021-09-14 | 2021-09-10+ | AUPH | Huizinga Robert Bindert | EVP of Research | S - Sale | $21.15 | -32.5K | 106.1K | -23% | -$687.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-09-10 | S | D | 5,000 | $19.76 | 128,592 | D | — | — | |
| 2 | Common | Common Stock | 2021-09-10 | S | D | 5,000 | $19.83 | 133,592 | D | — | — | |
| 3 | Common | Common Stock | 2021-09-14 | S | D | 22,500 | $21.75 | 106,092 | D | — | — |